查詢結果分析
相關文獻
- Cardiac Magnetic Resonance Imaging in Sunitinib Malate-related Cardiomyopathy: No Late Gadolinium Enhancement
- 由充血性心臟衰竭的治療進展談起--中醫研究之困境
- 醫師處方評估及病患用藥指導: 乙種維生素缺乏引起之心臟病變
- "HeartMate"心伴左心室輔助幫浦在重度心臟衰竭病人之應用
- Dopamine and Dobutamine Have Different Effects on Heart Rate Variability in Patients with Congestive Heart Failure
- Treatment of Heart Failure
- 病例介紹與用藥檢討(17)--鬱血性心臟衰竭(Congestive Heart Failure)
- Pacing Therapy in Congestive Heart Failure
- Ten-Year Study of Infective Endocarditis: Clinical Features at Different Locations
- Myocardial Effects of beta-Agonist Stimulation in Rats with Chronic Left Ventricular Dysfunction Treated with an Angiotensin-Converting Enzyme Inhibitor
頁籤選單縮合
題 名 | Cardiac Magnetic Resonance Imaging in Sunitinib Malate-related Cardiomyopathy: No Late Gadolinium Enhancement=與Sunitinib Malate相關之心肌病變的心臟核磁共振影像:無孔的延遲性顯影 |
---|---|
作 者 | 吳靜芬; 莊文博; 李愛先; 蕭吉晃; | 書刊名 | Journal of the Chinese Medical Association |
卷 期 | 72:6 2009.06[民98.06] |
頁 次 | 頁323-327+CA59 |
分類號 | 418.31 |
關鍵詞 | 心臟核磁共振造影; 心臟衰竭; 酪氨酸激酶抑制劑; Sunitinib; Cardiac magnetic resonance imaging; Heart failure; Tyrosine kinase inhibitor; |
語 文 | 英文(English) |
英文摘要 | Sunitinib malate, an oral multitargeted tyrosine kinase inhibitor (TKI), has been approved for the treatment of advanced renal cell carcinoma and gastrointestinal stromal tumors. It is supposed that this targeted approach improves antitumor activity with less toxicity than traditional chemotherapy. However, unanticipated cardiotoxicity related to TKIs has been reported. Less well described are the treatment and prognosis of patients with sunitinib-related cardiogenic shock. Here, we report a successfully treated case. In contrast to previous case reports, the shock status did not allow for standard heart failure treatment with angiotensin-converting enzyme inhibitor or beta-blocker. We used intra-aortic balloon counterpulsation, and the patient survived. Twenty-four days after onset, the patient’s left ventricular ejection fraction had improved from 20% to 48%. To the best of our knowledge, this is the first case report of severe heart failure after sunitinib treatment in Taiwan. As the clinical application of TKIs expands, cardiologists and oncologists should be alert to the possible adverse cardiovascular effects and be ready to institute prompt treatment. |
本系統中英文摘要資訊取自各篇刊載內容。